www.HIVdent.org

 

Medication Information

 

Featured Articles

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

aidsinfo | December 2018

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

AIDSinfo | October 25, 2018

Meta-analysis of the risk of Grade 3/4 or serious clinical adverse events in 12 randomised trials of PrEP
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
Department of Health and Human Services Adults and Adolescents Antiretroviral Guidelines Panel* Classifies a Fixed-Dose Combination Product of Bictegravir/Tenofovir Alafenamide/Emtricitabine as One of the Recommended Initial Regimens for Most People with HIV
AIDSinfo |  March 27, 2018
Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication - Risk of Serious Liver Injury
NASTAD Release: ADAP Formulary Database
HIV/AIDS Update- Prezista (darunavir) labeling changes
FDA April 24, 2013
The 17th Annual HIV Drug Guide
Positively Aware, Test Positive Aware Network
Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases (PDF)
Updated Hepatitis C Practice Guidelines Now Available from AASLD
ARLINGTON, Va., Sept. 28, 2011 /PRNewswire via COMTEX/
The updated Perinatal Guidelines (September 14, 2011) are Available
Chantix (varenicline): Label Change - Risk of Certain Cardiovascular Adverse Events
FDA 07/22/2011
Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-Analyses
Gastroenterology 30 July 2009
TAG 2010 Pipeline Report (PDF)
New FDA Hepatitis List Serve
Enhanced Drug Fact Sheets on AIDSInfo AETC National Resource Center
Reyataz (atazanavir) Package Insert Revisions

News Updates

HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy

AIDS: March 1, 2019

U.S. FDA Accepts sNDAs for PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate)
Merck | January 22, 2019

Pharm To Exam Table – Candida glabrata Urinary Tract Infections

University of Nebraska Medical Center | December 21, 2018

Note from Dr. Reznik – This information is valuable for oral infections with Candida glabrata

HIV EMAIL UPDATES

FDA | December 11, 2018

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

The Lancet | November 9, 2018

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

PLoS Med. 2018 Nov 8;15(11):e1002690. doi: 10.1371/journal.pmed.1002690. eCollection 2018 Nov

FDA HIV Update: GENVOYA, STRIBILD, and TYBOST Pregnancy Label

FDA | November 7, 2018

Novel antibiotic shows promise in treatment of uncomplicated gonorrhea

NIH | November 7, 2018

NASTAD Announces the Release of PrEPcost.org

NASTAD | November 6, 2018

Development of an End-user Informed Tenofovir Alafenamide (TAF) Implant for Long-acting (LA)-HIV Pre-exposure Prophylaxis (PrEP)

NATAP | November 6, 2018

Transgender women taking PrEP have lower levels of PrEP drugs, especially in rectal tissues, than ...

aidsmap | November 2018

Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant patients ...

aidsmap | November 2, 2018

Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir

aidsmap | November 1, 2018

FDA HIV Update- ODEFSEY/COMPLERA: Pregnancy Label Updates

FDA | October 31, 2018

ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Two Thirds Reach Sub-50 Viral Load Through 48 Weeks With Ibalizumab

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Polypharmacy in One Third of Big HIV Cohort vs One Fifth of Non-HIV Group
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
Good HIV Response Rate, Sustained Safety Through 96 Weeks With D/C/F/TAF
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Outcomes of Patients Not Achieving Primary Endpoint From an Ibalizumba Phase 3 Trial

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Bictegravir/F/TAF Noninferior to DTG Plus F/TAF at 96 Weeks: No Resistance
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
Viral Decay Similar With 2- and 3-Drug Dolutegravir Regimens
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Predicting two-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Bictegravir/F/TAF at 96 Weeks With High Baseline Viral Load or Low CD4 Count
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Neural tube defects and integrase inhibitors: studies show no further evidence of increased risk

aidsmap | October 30, 2018

New and Updated HIV Drug Facts Sheets from AIDSinfo

AIDSinfo | Oct 4, 2018

Studies confirm long-term effectiveness of new single-tablet regimens

aidsmap | October 8, 2018

GS-6207: A Novel, Potent and Selective First-In-Class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in Humans

Dual-antibody combination therapy produces three to seven months of viral suppression without pills

aidsmap | October 8, 2018

Janssen Reports Switching to SYMTUZA™ Results in Maintained High Virologic Suppression and No Resistance Development up to 96-Weeks in Virologically Suppressed Adults with HIV-1

IDWeek 2018, October 3-7, 2018, San Francisco

Sustained Viral Suppression After Switch to Darunavir/Dolutegravir
IDWeek 2018, October 3-7, 2018, San Francisco
Mail-Order Pharmacy, Travel Time to Pharmacy Do Not Affect HIV Control
IDWeek 2018, October 3-7, 2018, San Francisco

Truvada ruling could allow cheap HIV prevention in the UK

pharmaphorum | Sept 19, 2018

FDA HIV Update- New HIV drug approvals

FDA | Sept 4, 2018

Dolutegravir-based ART effective and safe for HIV-positive people taking standard TB treatment

aidsmap | August 24, 2018

Ibalizumab: A new treatment option for MDR HIV-1

Healio | August 2018

Swapping daily pills for monthly shots could transform HIV treatment and prevention

Science Magazine | August 22, 2018

Neuropsychiatric side-effects lead only 1 in 40 to drop dolutegravir, French study shows

aidsmap | August 22, 2018

New Drug of Last Resort Tackles Resistant HIV

WebMD | August 16, 2018

FDA HIV Update: Label Change for Genvoya, Stribild and Tybost

FDA | August 13, 2018

FDA Hepatitis Update- Mavyret (glecaprevir and pibrentasvir) Label Change

FDA | August 8, 2018

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for GARDASIL®9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases

Wednesday, June 13, 2018

Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain

NATAP | January 17, 2018

"Rates of STI were higher among participants taking PrEP as compared to participants not taking PrEP

JAIDS July 25 2018

FDA Approves Drug For Thrombocytopenia In Patients With Chronic Liver Disease.

Reuters | July 31, 2018

New Study Shows Improvement Needed in Outpatient Antibiotic Prescribing

07/16/2018

Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure

JACC | July 2018

Switching to E/C/F/TAF effective in people with historical M184V/I mutation
22nd International AIDS Conference, Amsterdam, Netherlands, July 23-27, 2018

Pfizer and GSK's HIV/AIDS division, ViiV, prevents children with HIV from getting needed medicine

Médecins Sans Frontières (MSF) International | July 23, 2018

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

Lancet HIV July 2018

Status report on HIV AIDS in children and youth of western and central Africa

Devdiscourse | July 29, 2018

HIV Email Updates

FDA | July 18, 2018

Janssen receives FDA approval for Symtuza

Healio | July 18, 2018

Pharma giant Merck just lowered the prices of some of its medications

Business Insider | July 12, 2018

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2018 Recommendations of the International Antiviral Society–USA Panel
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development
2018 Pipeline Report, TAG
HIV Email Updates
CDC | July 14, 2018
Patient‑Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double‑Blind, Phase III Non‑inferiority Trials of Adults with HIV on Co‑formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co‑formulated Abacavir, Dolutegravir, and Lamivudine
Hepatitis Update
FDA | July 5, 2018
Study: AIDS Drug Not Linked to Depression, Suicide
VOA Learning English | July 3, 2018
Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including ...
Business Wire | July 2, 2018
European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Business Wire | June 25, 2018
ViiV Healthcare reports positive results for landmark phase III studies for dolutegravir and lamivudine
China approves Albuviritide: first domestically developed, long-acting injectable anti-HIV drug
Firstpost June 6, 2018
HIV Email Updates
FDA | June 5, 2018
Theratechnologies Announces Agreement With AIDS Drug Assistance Program (ADAP) for ...
GlobeNewswire | May 23, 2018
Elvitegravir pharmacokinetics during pregnancy and postpartum
19th International Workshop on Clinical Pharmacology of Antiviral Therapy
First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women  
19th International Workshop on Clinical Pharmacology of Antiviral Therapy
Differing drug distribution in penis and rectum of men taking TDF/FTC PrEP
19th International Workshop on Clinical Pharmacology of Antiviral Therapy
U.S. Food and Drug Administration, Drug Safety Communication on the potential risk of antiretroviral medication dolutegravir (DTG)
FDA | May 18, 2018
HIV Email Updates
May 15, 2018
Pediatric HIV Infection: Drug Development for Treatment
FDA | May 2018

   
  Past Medication News Updates